The DDI Advisory Board, which bolsters our strategic direction, consists of internationally recognized experts with proven track records in pharmaceutical drug discovery, development and commercialization.
- Holds meetings three times per year and ad hoc meetings as needed
- Engages and interacts frequently with the DDI team
- Conducts scientific reviews of proposed and ongoing projects
- Manages pipeline
- Offers guidance for business development and licensing opportunities
John Byrd, MD
Dr. Byrd is a Distinguished University Professor of Medicine. He is the co-leader of the leukemia research program and manages the Experimental Hematology Laboratory. He holds the D. Warren Brown Endowed Chair of Leukemia Research at the at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). He is a physician scientist focused on immune and molecular pharmacology and clinically on developing new treatments for acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). He has more than 400 publications related to his work. Dr. Byrd has participated in the comprehensive development of five drugs that ultimately have been FDA approved for CLL and AML.
Zihai Li, MD, PhD
Dr. Li is a renowned medical oncologist and immunologist and the founding director of the new Pelotonia Institute for Immuno-Oncology (PIIO) at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). The PIIO is a bench-to-bedside research initiative that focuses on harnessing the immune system to fight cancer at all levels, from prevention to treatment and survivorship. Dr. Li is also a professor in the Department of Internal Medicine at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James, where he specializes in studying mechanisms of immune regulation in cancer. His current interests focus on developing better immunotherapeutics against this disease by reprogramming the tumor microenvironment.
David Carbone, MD, PhD
Dr. Carbone is a professor of Internal Medicine, director of the OSUCCC – James Thoracic Oncology Center and the Barbara J. Bonner Chair in Lung Cancer Research. He is a world-renowned lung cancer expert with over 200 peer-reviewed publications.
Pat Confalone, PhD
Dr. Confalone is an R&D consultant at Confalone Consulting, LLC. He has over 46 years of R&D experience and is an expert in medicinal chemistry, process R&D, and preclinical development. He was previously VP at DuPont, VP at Bristol-Myers Squibb, SVP at DuPont Merck Pharmaceuticals and Chairman of the Board of the American Chemical Society.
Bobby Sandage, PhD
Dr. Sandage is the president and CEO of Euclises, General Partner in Cultivation Capital Life Sciences Fund II. He brings over 35 years of pharmaceutical research and development experience. He was formerly president and CEO of Coronado Biosciences, head of oncology program at Covidien Pharmaceuticals, EVP and chief scientific officer at Indevus Pharmaceuticals, and has held senior drug development positions at DuPont Merck. Additionally, he remains an active board member of Mateon (MATN), Immunophotonics and Tensive Controls.
Robert Stein, MD, PhD
Dr. Stein is a senior advisor and former president of R&D at Agenus Inc. He brings over 35 years of experience in innovation and leadership in the Pharma and Biotech industries. Previously, he was executive vice president (EVP) of research & development for DuPont Merck Pharmaceuticals, president of R&D and chief scientific officer (CSO) for Incyte Pharmaceuticals, president of Roche Palo Alto and CEO of KineMed.
Andrew Dahlem, DVM (h.c), PhD
Dr. Dahlem is chief of the Division of Clinical Pharmacology and senior research professor of Medicine at Indiana University School of Medicine. He has previously served as VP and COO of Lilly Research Laboratories (LRL) and led the Lilly Research Operations Group to advance drug discovery, molecule and technology acquisition, and business development efforts.
For more information, contact the DDI at email@example.com.